Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
A non-digestible oligosaccharide, Bifidobacterium breve technology, applied in the field of nutrition for infants and/or young children, can solve problems such as not involving nutritional formula, and achieve the effect of reducing pollution of harmful microorganisms
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0078] Example 1: Non-viable Bifidobacterium breve has anti-allergic effect
[0079] Male BALB / c mice (6-8 weeks old) were obtained from Charles River (Someren, The Netherlands). Mice were housed individually in Type II cages with semi-synthetic chow (AING93) (based on the American Institute of Nutrition (1993) growth formula) and water provided ad libitum. Mice were divided into different treatment groups A-D (N=6), and each group was divided into two groups of 3 animals. The start of the second cohort is delayed by a week.
[0080] Active sensitization was performed by two intraperitoneal injections on days 0 and 7. Mice in the negative control group (group A) were sensitized by intraperitoneal injection with phosphate buffered saline (PBS) containing 2.25 mg aluminum hydroxide and 2.25 magnesium hydroxide as adjuvants (Alum inject, Pierce) in a volume of 100 μl. sensitive. Other groups of mice were injected intraperitoneally with 10 μg ovalbumin (OVA) in PBS (0.2 μm f...
Embodiment 2
[0088] Example 2: The combination of non-viable Bifidobacterium breve and non-digestible oligosaccharides has enhanced anti-allergic effect compared to the single components.
[0089] CH3 / HeOuJ mice (3-5 weeks old) were obtained from Charles River. Mice were housed individually in Type II cages with semi-synthetic, milk protein-free chow and water provided ad libitum. Mice were divided into different treatment groups A-E (N=6) for 2 weeks. The different treatment groups A-E (N=6) include negative control group (A group), positive control group (B group), receiving 2×10 per gram of diet 9 The group (Group C) of CFU Bifidobacterium breve M16-V (heat inactivated at 90°C for 10 minutes), received 20 mg per gram of diet non-digestible oligosaccharides (TOS (from Vivinal GOS, Borculo Domo) and lcFOS (Raftilin HP , Orafti), the group (group D) with a weight ratio of 9 / 1) and the group that received heat-killed B. breveensis and non-digestible oligosaccharides (group E). Therefore,...
Embodiment 3
[0097] Example 3: Liquid children's milk containing Bifidobacterium breve
[0098] Liquid, ready-to-eat growing up milk, which contains per 100ml:
[0099] -67 kcal
[0100] -1.9g protein (milk protein)
[0101] -8.1g digestible carbohydrates (of which 7.8g lactose)
[0102] -3.0g fat
[0103] -0.8g non-digestible oligosaccharides:
[0104] 0.72 Galactooligosaccharides from Vivival GOS
[0105] 0.08g fructan from RaftilinHP
[0106] - Equivalent to 5.10 9 heat-killed Bifidobacterium breve cfu
[0107] The pH is about 6.7.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com